Top Stories
Since its first mission launched in 2023, Varda has completed six reentry missions with over a dozen more launches and reentries planned through 2028.
The company said tulisokibart, designed to help address immuno-fibrosis, posted up to a 72% HiSCR50 response at week 16 in Phase II testing.
Roche and Zealand's amylin analogue showed weight loss peaked at the 5-mg dose, where patients achieved a 9.8% reduction.
The real-world data showed that people who switched from injectable GLP-1 based therapies to oral Wegovy (semaglutide) lost an average of 4.1% of their body weight in three months
Beam alleges YOLT-202 was copied from BEAM-302 after researcher Zi Jun Wang allegedly accessed confidential data before leaving the company.
Conference News
The presentation will showcase advancements in the development of BIO 300 (BYOGRAYZ™) Injectable Suspension, an investigational prophylactic Medical Countermeasure (MCM) being developed to prevent rad...
HANGZHOU, China, Sept. 30, 2026 /PRNewswire/ -- At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind") today announ...
Patients treated with delandistrogene moxeparvovec at ages 8-12 demonstrated durable and clinically meaningful benefits across the North Star Ambulatory Assessment and timed function measures over 2 y...
Oslo, Norway – 30 September 2026 –Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdomi...
JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile designed for infrequent subcutaneous dosing JADE301 demonstrated high-affinity, selective IFN-β bin...
